> Details

Matino, Erica; Tavella, Elena; Rizzi, Manuela; Avanzi, Gian Carlo; Azzolina, Danila; Battaglia, Antonio; Becco, Paolo; Bellan, Mattia; Bertinieri, Giovanni; Bertoletti, Massimo; Casciaro, Giuseppe Francesco; Castello, Luigi Mario; Colageo, Umberto; Colangelo, Donato; Comolli, Davide; Costanzo, Martina; Croce, Alessandro; D’Onghia, Davide; Della Corte, Francesco; De Mitri, Luigi; Dodaro, Valentina; Givone, Filippo; Gravina, Alessia; Grillenzoni, Luca; [...]

Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial

Reference
management

Bookmarks

Remove from
bookmarks

Share this on Whatsapp

Close

Bookmarks



You can manage bookmarks using lists, please log in to your user account for this.
  • Media type: E-Article
  • Title: Effect of Lactoferrin on Clinical Outcomes of Hospitalized Patients with COVID-19: The LAC Randomized Clinical Trial
  • Contributor: Matino, Erica; Tavella, Elena; Rizzi, Manuela; Avanzi, Gian Carlo; Azzolina, Danila; Battaglia, Antonio; Becco, Paolo; Bellan, Mattia; Bertinieri, Giovanni; Bertoletti, Massimo; Casciaro, Giuseppe Francesco; Castello, Luigi Mario; Colageo, Umberto; Colangelo, Donato; Comolli, Davide; Costanzo, Martina; Croce, Alessandro; D’Onghia, Davide; Della Corte, Francesco; De Mitri, Luigi; Dodaro, Valentina; Givone, Filippo; Gravina, Alessia; Grillenzoni, Luca; [...]
  • imprint: MDPI AG, 2023
  • Published in: Nutrients
  • Language: English
  • DOI: 10.3390/nu15051285
  • ISSN: 2072-6643
  • Keywords: Food Science ; Nutrition and Dietetics
  • Origination:
  • Footnote:
  • Description: <jats:p>As lactoferrin is a nutritional supplement with proven antiviral and immunomodulatory abilities, it may be used to improve the clinical course of COVID-19. The clinical efficacy and safety of bovine lactoferrin were evaluated in the LAC randomized double-blind placebo-controlled trial. A total of 218 hospitalized adult patients with moderate-to-severe COVID-19 were randomized to receive 800 mg/die oral bovine lactoferrin (n = 113) or placebo (n = 105), both given in combination with standard COVID-19 therapy. No differences in lactoferrin vs. placebo were observed in the primary outcomes: the proportion of death or intensive care unit admission (risk ratio of 1.06 (95% CI 0.63–1.79)) or proportion of discharge or National Early Warning Score 2 (NEWS2) ≤ 2 within 14 days from enrollment (RR of 0.85 (95% CI 0.70–1.04)). Lactoferrin showed an excellent safety and tolerability profile. Even though bovine lactoferrin is safe and tolerable, our results do not support its use in hospitalized patients with moderate-to-severe COVID-19.</jats:p>
  • Access State: Open Access